Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct;67(10):e28277.
doi: 10.1002/pbc.28277. Epub 2020 Aug 11.

Retrospective study of hematologic complications in patients with slow-flow vascular malformations undergoing sclerotherapy

Kiersten W Ricci  1 , Carol Chute  1 , Adrienne M Hammill  1 , Roshni Dasgupta  2 , Manish Patel  3
Affiliations

Retrospective study of hematologic complications in patients with slow-flow vascular malformations undergoing sclerotherapy

Kiersten W Ricci et al. Pediatr Blood Cancer. 2020 Oct.

Abstract

Background: Slow-flow vascular malformations (SFVM) are associated with localized intravascular coagulopathy (LIC), which is characterized by elevated D-dimer and, when severe, hypofibrinogenemia. LIC results in intralesional clotting and hemorrhage and increases risk for significant thrombotic and bleeding complications. Sclerotherapy has been a suggested potential trigger for LIC worsening to disseminated intravascular coagulopathy. Hematologic complications of sclerotherapy in SFVM, along with low-molecular-weight heparin (LMWH) used to prevent worsening LIC, are largely unstudied.

Procedure: Medical records of patients with SFVM and LIC who underwent sclerotherapy at Cincinnati Children's Hospital Medical Center from July 2008 to December 2016 were reviewed for periprocedural hematologic complications. LMWH dose, frequency, and course length were evaluated.

Results: Fifty-nine patients with SFVM and LIC underwent 281 sclerotherapy procedures, of which 86% were in children. Eighty-five percent of patients received periprocedural LMWH, although at various doses and course lengths. No thrombotic complications occurred in children. One adult on LMWH developed pulmonary emboli after sclerotherapy. No major bleeding complications occurred postoperatively. In four patients, fibrinogen dropped below 100 mg/dL post-sclerotherapy, requiring cryoprecipitate. One patient required packed red blood cell (RBC) transfusion for sclerotherapy-induced hemolysis. No intraoperative bleeding or thrombotic events occurred.

Conclusion: LMWH use, at subtherapeutic dosing, was common in this patient population and did not appear to increase risk of significant bleeding before, during, or after sclerotherapy. In children with SFVM, bleeding and thrombotic complications after sclerotherapy appear rare. Although safe, prospective studies are needed to evaluate the efficacy of LMWH to prevent worsening coagulopathy with procedures.

Keywords: anticoagulation; coagulopathy; hematologic complication; low-molecular-weight heparin (LMWH); sclerotherapy; vascular malformation.

PubMed Disclaimer

References

REFERENCES

    1. Eifert S, Villavicencio JL, Kao T-C, et al. Prevalence of deep venous anomalies in congenital vascular malformations of venous predominance. J Vasc Surg. 2000;31(3):462-471.
    1. Oduber CE, Gerdes VE, van der Horst CM, et al. Vascular malformations as underlying cause of chronic thromboembolism and pulmonary hypertension. J Plast Reconstr Aesthet Surg. 2009;62(5):684-689. discussion 689.
    1. van Es J, Kappelhof NA, Douma RA, et al. Venous thrombosis and coagulation parameters in patients with pure venous malformations. Neth J Med. 2017;75(8):328-334.
    1. Mazoyer E, Enjolras O, Bisdorff A, et al. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol. 2008;144(7):861-867.
    1. Gloviczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. Phlebology. 2007;22(6):291-298.